DDInter1679 DDInter1763
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Sitagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Sitagliptin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Sitagliptin {u} (Compound) downregulates {v} (Gene) TCEA2
TCEA2 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Sitagliptin {u} (Compound) upregulates {v} (Gene) MELK
MELK {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Sitagliptin {u} (Compound) causes {v} (Side Effect) Pharyngitis
Pharyngitis {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Sitagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Sitagliptin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Sitagliptin {u} (Compound) downregulates {v} (Gene) TCEA2
TCEA2 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Sitagliptin {u} (Compound) downregulates {v} (Gene) CTNND1
CTNND1 {u} (Gene) is regulated by {v} (Gene) MKNK1
MKNK1 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Sitagliptin {u} (Compound) downregulates {v} (Gene) BPHL
BPHL {u} (Gene) is downregulated by {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Temsirolimus
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Sitagliptin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Sitagliptin (Compound) downregulates TCEA2 (Gene) and TCEA2 (Gene) is upregulated by Temsirolimus (Compound)
Sitagliptin (Compound) upregulates MELK (Gene) and MELK (Gene) is downregulated by Temsirolimus (Compound)
Sitagliptin (Compound) causes Pharyngitis (Side Effect) and Pharyngitis (Side Effect) is caused by Temsirolimus (Compound)
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Sitagliptin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Sitagliptin (Compound) downregulates TCEA2 (Gene) and TCEA2 (Gene) is upregulated by Sirolimus (Compound) and Sirolimus (Compound) resembles Temsirolimus (Compound)
Sitagliptin (Compound) downregulates CTNND1 (Gene) and CTNND1 (Gene) is regulated by MKNK1 (Gene) and MKNK1 (Gene) is upregulated by Temsirolimus (Compound)
Sitagliptin (Compound) downregulates BPHL (Gene) and BPHL (Gene) is downregulated by kidney cancer (Disease) and kidney cancer (Disease) is treated by Temsirolimus (Compound)